Yi Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yi Li has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Alan Shupe
Biologics Process Development, Global Manufacturing and Supply, Bristol-Myers Squibb, Hopkinton, MA, United States
1 shared publicationChristopher G Boissard
Department of Neuroscience Drug Discovery, The Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
1 shared publicationGraham Johnson
Department of Discovery Chemistry, The Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
1 shared publicationJeffrey L Romine
Department of Discovery Chemistry, The Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
1 shared publicationJohn E Starrett
Department of Discovery Chemistry, The Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
1 shared publicationKevin Bai
Mass Spectrometry and Biophysics Center of Excellence, Molecular and Analytical Development Technology, Bristol-Myers Squibb, Hopewell, NJ, United States
1 shared publication
Latest Publications
- 28 May 2015
- Published by Elsevier in Journal of Chromatography A
- Vol. 1404, 51-59
Heterogeneous glycoform separation by process chromatography: I
- 28 May 2015
- Published by Elsevier in Journal of Chromatography A
- Vol. 1404, 51-59
Heterogeneous glycoform separation by process chromatography: I
- 6 May 2015
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 112 (11) , 2292-2304
Development of robust antibody purification by optimizing protein‐A chromatography in combination with precipitation methodologies
To be administered to patients, therapeutic monoclonal antibodies must have very high purity, with process related impurities like host‐cell proteins (HCPs) and DNA reduced to <100 ppm and <10 ppb, respectively, relative to desired product. Traditionally, Protein‐A chromatography as a capture step has been the work horse for clearing a large proportion of these impurities. However, remaining levels of process and product related impurities still present significant challenges on the development of polishing steps further downstream. In this study, we have incorporated high throughput screening to evaluate three areas of separation: (i) Harvest treatment; (ii) Protein‐A Chromatography; and (iii) Low pH Viral Inactivation. Precipitation with low pH treatment of cell culture harvest resulted in selective removal of impurities while manipulating the pH of wash buffers used in Protein‐A chromatography and incorporating wash additives that disrupt various modes of protein–protein interaction resulted in further and more pronounced reduction in impurity levels. In addition, our study also demonstrate that optimizing the neutralization pH post Protein‐A elution can result in selective removal of impurities. When applied over multiple mAbs, this optimization method proved to be very robust and the strategy provides a new and improved purification process that reduces process related impurities like HCPs and DNA to drug substance specifications with just one chromatography column and open avenues for significant decrease in operating costs in monoclonal antibody purification. Biotechnol. Bioeng. 2015;112: 2292–2304.
- 6 May 2015
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 112 (11) , 2292-2304
Development of robust antibody purification by optimizing protein‐A chromatography in combination with precipitation methodologies
To be administered to patients, therapeutic monoclonal antibodies must have very high purity, with process related impurities like host‐cell proteins (HCPs) and DNA reduced to <100 ppm and <10 ppb, respectively, relative to desired product. Traditionally, Protein‐A chromatography as a capture step has been the work horse for clearing a large proportion of these impurities. However, remaining levels of process and product related impurities still present significant challenges on the development of polishing steps further downstream. In this study, we have incorporated high throughput screening to evaluate three areas of separation: (i) Harvest treatment; (ii) Protein‐A Chromatography; and (iii) Low pH Viral Inactivation. Precipitation with low pH treatment of cell culture harvest resulted in selective removal of impurities while manipulating the pH of wash buffers used in Protein‐A chromatography and incorporating wash additives that disrupt various modes of protein–protein interaction resulted in further and more pronounced reduction in impurity levels. In addition, our study also demonstrate that optimizing the neutralization pH post Protein‐A elution can result in selective removal of impurities. When applied over multiple mAbs, this optimization method proved to be very robust and the strategy provides a new and improved purification process that reduces process related impurities like HCPs and DNA to drug substance specifications with just one chromatography column and open avenues for significant decrease in operating costs in monoclonal antibody purification. Biotechnol. Bioeng. 2015;112: 2292–2304.
- 13 March 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (8) , 1437-1439
Novel Openers of Ca2+-Dependent Large-Conductance Potassium Channels: Symmetrical Pharmacophore and Electrophysiological Evaluation of Bisphenols
- 13 March 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (8) , 1437-1439
Novel Openers of Ca2+-Dependent Large-Conductance Potassium Channels: Symmetrical Pharmacophore and Electrophysiological Evaluation of Bisphenols
- 1 January 2002
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 8 (2) , 99-110
A Review of Molecular Modeling Approaches to Pharmacophore Models and Structure-Activity Relationships of Ion Channel Modulators in CNS
Through pharmacophore models and providing quantitative analysis of structure-activity relationships (QSAR), molecular modeling techniques can be useful tools to study the interactions of ion channels and their modulators. The present review focuses on molecular modeling approaches that defined pharmacophore models of ion channel modulators in the CNS. The commonality and subtlety of the pharmacophore models of various ion channel modulators are discussed which can be used as a framework for the design of ion channel modulators.
- 1 January 2002
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 8 (2) , 99-110
A Review of Molecular Modeling Approaches to Pharmacophore Models and Structure-Activity Relationships of Ion Channel Modulators in CNS
Through pharmacophore models and providing quantitative analysis of structure-activity relationships (QSAR), molecular modeling techniques can be useful tools to study the interactions of ion channels and their modulators. The present review focuses on molecular modeling approaches that defined pharmacophore models of ion channel modulators in the CNS. The commonality and subtlety of the pharmacophore models of various ion channel modulators are discussed which can be used as a framework for the design of ion channel modulators.